ArticleIn vivo (Athens, Greece)
Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case report and medication implications: bilateral atypical femoral fractures in a patient with long-term bisphosphonate use after breast cancer surgery.Archives of osteoporosis · 2026Article
- Anabolics in Cancer Patients: To Use or Not to Use?Endocrinology and metabolism (Seoul, Korea) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBreast cancer frequently metastasizes to bone, and chemotherapy and hormone therapy can increase osteoporosis risk. Teriparatide (TPTD), an osteoporosis treatment that promotes bone formation, is contraindicated in patients with bone metastases due to concerns about osteosarcoma in animal studies. However, its effects on metastatic bone tumors remain unclear. This study aimed to evaluate TPTD's effects on breast cancer bone metastases using a mouse model. MATERIALS AND
methodsC57BL/6 mice were injected with E0771 breast cancer cells to establish bone metastasis and breast cancer models. Mice were assigned to the vehicle-treated group (control) or to the TPTD-treated group (80 μg/kg, subcutaneously three times weekly). Tumor weight, volume, bone destruction, pathological fractures, distant metastasis, tumor proliferation (Ki-67, BrdU), and bone microstructure were assessed at 4 and 6 weeks.
resultsIn both models, no significant differences in tumor weight or volume were observed between the TPTD and control groups. In the bone metastasis model, bone destruction and pathological fractures were not significantly different. No distant metastasis was observed and there were no significant differences in the percentages of Ki-67-positive and BrdU-positive cells in both models. In the bone microstructure analysis at 6 weeks post-injection, bone volume/tissue volume and trabecular thickness increased in the bone metastasis model in the TPTD group (
conclusionTPTD did not cause tumor growth, pathological fractures, or bone destruction in our
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.